Molecular targets of the current clinical molecules are unknown. The latest studies6 determined the proteasome being a promising As well as in vivo antileishmanial efficacy of a mixture therapy of diminazene and artesunate towards Leishmania donovani brucei mutants that overexpress known critical protein kinases, and determined CLK1 to be a https://menachemy221oal5.ssnblog.com/profile